First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin’s lymphoma-Reference-Cited by-同舟云学术

First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin’s lymphoma

Published:2016-11-28 Issue:2 Volume:52 Page:310-312
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Ghez D, ,Fortpied C,Mounier N,Carde P,Perrot A,Khaled H,Amorim S,Ramadan S,Bras F L,Erlanson M,Herbaux C,Marolleau J-P,Nicolas-Virelezier E,Casasnovas O,Stamatoullas-Bastard A,Fermé C

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2016271.pdf

Reference12 articles.

1. Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011; 29: 4234–4242.

2. Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009; 27: 4548–4554.

3. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791–1799.

4. Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27: 805–811.

5. Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ⩾4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 2014; 25: 1622–1628.